Kidney Cancer Coverage from Every Angle
Editor:
Robert J. Motzer, MD
Advertisement
Advertisement

Videos

Daniel P. Petrylak, MD, on Supporting Patients Considering a Clinical Trial

Thomas Powles, MD, PhD, on Using Nivolumab and Ipilimumab in Renal Cell Carcinoma

Leonard J. Appleman, MD, PhD, on Pazopanib After Metastasectomy in Renal Cell Carcinoma

Jonathan E. Rosenberg, MD, on Clinical Implications of Adding Bevacizumab to Gemcitabine/Cisplatin in Urothelial Carcinoma

Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Combining Checkpoint Inhibitors With Targeted Treatment

Daniel P. Petrylak, MD, on Toxicities in Nivolumab or Ipilimumab for Urothelial Cancer

Eric Jonasch, MD, on Managing Hepatotoxicity in Patients Treated With Pazopanib

Nicholas Vogelzang, MD, on Urothelial Cancer: Lenvatinib Plus Pembrolizumab

Rana R. McKay, MD, on Kidney Cancer: What Complete Remission Means for Patients

Rana R. McKay, MD, on Renal Cell Carcinomas: The Potential Role for Atezolizumab and Bevacizumab

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on Metastatic RCC: Perspectives on the Carmena Trial

Bernard J. Escudier, MD, on RCC: How the IMmotion151 Results Could Improve Treatment

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease

Ulka N. Vaishampayan, MD, on Renal Cancer: The Personalized Approach to Treatment

Chung-Han Lee, MD, PhD, on Maintaining Weight During Treatment

Eric Jonasch, MD, on Kidney Cancer: Management Updates

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Guidelines and Guidance

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient's Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Jonathan E. Rosenberg, MD, on Nivolumab Monotherapy for Urothelial Carcinoma

Laurence Albiges, MD, PhD, on RCC: Update on Checkpoint Inhibitors

Thomas Powles, MD, on Atezolizumab vs Chemotherapy in Urothelial Carcinoma

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Mollie Reed, MSN, RN, ACNP-BC, on Managing Rash Linked to TKIs

Robert A. Figlin, MD, on Managing TKI-Induced Diarrhea

Rohann J.M. Correa, MD, PhD, on RCC: Ablative Radiation vs Nephrectomy

Anurag Singh, MD, on RCC: Findings From an SBRT Pilot Study

Toni K. Choueiri, MD, and Michael D. Staehler, MD, PhD, on RCC: Results From the SWITCH-II and SURTIME Trials

Daniel P. Petrylak, MD, on Urothelial Carcinoma: Results of the RANGE Trial

Petros Grivas, MD, PhD, on Urothelial Carcinoma Roundup: Expert Perspective

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on Urothelial, RCC, and Other GU Malignancies: Two Key Trials

Eric Jonasch, MD, on RCC and Sunitinib: Phase II Trial Results

Robert J. Motzer, MD, and Toni Choueiri, MD: Results of the PROTECT Trial

Toni Choueiri, MD, on Newer Agents in the Treatment of Renal Cell Carcinoma

Eric Jonasch, MD, on Kidney Cancer: Incorporating New Systemic Therapies

Robert J. Motzer, MD, on NCCN Kidney Cancer Guidelines: Process, Evolution, and Clinical Practice

Toni K. Choueiri, MD, and Bernard J. Escudier, MD, on RCC: Trial Results on Sunitinib

Emily Lemke, DNP, AGPCNP-BC, AOCNP, on Managing TKI-Induced Diarrhea

Petros Grivas, MD, PhD, on Managing TKI-Induced Diarrhea

Michael B. Atkins, MD, and Eric Jonasch, MD, on Metastatic Renal Cell Carcinoma: Results From the IMmotion150 Trial

The JNCCN Spotlight

Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.